Krystal Biotech Stock Alpha and Beta Analysis

KRYS Stock  USD 181.10  5.79  3.10%   
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Krystal Biotech. It also helps investors analyze the systematic and unsystematic risks associated with investing in Krystal Biotech over a specified time horizon. Remember, high Krystal Biotech's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Krystal Biotech's market risk premium analysis include:
Beta
0.37
Alpha
0.0778
Risk
3.08
Sharpe Ratio
(0.03)
Expected Return
(0.10)
Please note that although Krystal Biotech alpha is a measure of relative return and represented here as a single number, it indicates the percentage above or below your selected benchmark (i.e., Dow Jones Industrial index.) So in this particular case, Krystal Biotech did 0.08  better than the index. Remember, a high alpha is always good. Beta, on the other hand, measures the volatility (or risk) of an investment. It is an indication of Krystal Biotech stock's relative risk over its benchmark. Krystal Biotech has a beta of 0.37  . As returns on the market increase, Krystal Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Krystal Biotech is expected to be smaller as well. At this time, Krystal Biotech's Book Value Per Share is comparatively stable compared to the past year. Tangible Book Value Per Share is likely to gain to 34.75 in 2025, whereas Price Book Value Ratio is likely to drop 4.50 in 2025.

Enterprise Value

2.85 Billion

Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
  
Check out Krystal Biotech Backtesting, Krystal Biotech Valuation, Krystal Biotech Correlation, Krystal Biotech Hype Analysis, Krystal Biotech Volatility, Krystal Biotech History and analyze Krystal Biotech Performance.
For more information on how to buy Krystal Stock please use our How to Invest in Krystal Biotech guide.

Krystal Biotech Market Premiums

Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Krystal Biotech market risk premium is the additional return an investor will receive from holding Krystal Biotech long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Krystal Biotech. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Krystal Biotech's performance over market.
α0.08   β0.37

Krystal Biotech expected buy-and-hold returns

Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Krystal Biotech's Buy-and-hold return. Our buy-and-hold chart shows how Krystal Biotech performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.

Krystal Biotech Market Price Analysis

Market price analysis indicators help investors to evaluate how Krystal Biotech stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Krystal Biotech shares will generate the highest return on investment. By understating and applying Krystal Biotech stock market price indicators, traders can identify Krystal Biotech position entry and exit signals to maximize returns.

Krystal Biotech Return and Market Media

The median price of Krystal Biotech for the period between Thu, Nov 28, 2024 and Wed, Feb 26, 2025 is 160.49 with a coefficient of variation of 9.09. The daily time series for the period is distributed with a sample standard deviation of 15.16, arithmetic mean of 166.74, and mean deviation of 13.23. The Stock received substential amount of media coverage during this period.
 Price Growth (%)  
       Timeline  
1
HC Wainwright Reaffirms Buy Rating for Krystal Biotech
12/18/2024
2
Is the Options Market Predicting a Spike in Krystal Biotech Stock
01/24/2025
3
Strength Seen in Ginkgo Bioworks Can Its 14.5 percent Jump Turn into More Strength
02/06/2025
4
Voyager Therapeutics, Inc. A Cheap Biotech Stock to Invest In Now
02/12/2025
5
Krystal Biotech Announces Fourth Quarter and Full Year 2024 Financial and Operating Results
02/19/2025
6
Chardan Capital Forecasts Strong Price Appreciation for Krystal Biotech Stock
02/20/2025
7
Krystal Biotech Upgraded to Buy Heres What You Should Know
02/21/2025
8
Why Krystal Biotech Might be Well Poised for a Surge
02/24/2025

About Krystal Biotech Beta and Alpha

For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Krystal or other stocks. Alpha measures the amount that position in Krystal Biotech has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
 2024 2025 (projected)
Days Sales Outstanding131.6238.84
PTB Ratio4.734.5

Krystal Biotech Upcoming Company Events

As portrayed in its financial statements, the presentation of Krystal Biotech's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Krystal Biotech's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Krystal Biotech's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Krystal Biotech. Please utilize our Beneish M Score to check the likelihood of Krystal Biotech's management manipulating its earnings.
26th of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
26th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

Build Portfolio with Krystal Biotech

Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.

Build Diversified Portfolios

Align your risk with return expectations

By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations

Additional Tools for Krystal Stock Analysis

When running Krystal Biotech's price analysis, check to measure Krystal Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Krystal Biotech is operating at the current time. Most of Krystal Biotech's value examination focuses on studying past and present price action to predict the probability of Krystal Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Krystal Biotech's price. Additionally, you may evaluate how the addition of Krystal Biotech to your portfolios can decrease your overall portfolio volatility.